 | • レポートコード：MRC2012A1290 • 出版社/出版日：GlobalInfoResearch / 2020年12月21日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、ベバシズマブバイオシミラーの世界市場を広く調査・分析し、今後の市場展望をまとめております。ベバシズマブバイオシミラーの種類別市場規模（100mg、400mg）、用途別市場規模（結腸直腸がん、肺がん、乳がん、腎がん、脳腫瘍、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、Celgene Corporation、Biocon、Allergan、Beaconpharma、Amgen、Hetero Drugs、Bevacizumab、Reliance lifesciences、Fujifilm Kyowa Kirin Biologics、 ・地域別グローバル市場分析 2015年-2020年 ・ベバシズマブバイオシミラーの北米市場（アメリカ、カナダ、メキシコ） ・ベバシズマブバイオシミラーのヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・ベバシズマブバイオシミラーのアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・ベバシズマブバイオシミラーの南米市場（ブラジル、アルゼンチン） ・ベバシズマブバイオシミラーの中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：100mg、400mg ・用途別分析：結腸直腸がん、肺がん、乳がん、腎がん、脳腫瘍、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Bevacizumab Biosimilar market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Bevacizumab Biosimilar market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Bevacizumab Biosimilar market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Bevacizumab Biosimilar market has been segmented into
100mg
400mg
By Application, Bevacizumab Biosimilar has been segmented into:
Colorectal Cancer
Lung Cancer
Breast Cancer
Renal Cancer
Brain Cancer
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Bevacizumab Biosimilar market presented in the report. This section sheds light on the sales growth of different regional and country-level Bevacizumab Biosimilar markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Bevacizumab Biosimilar market.
The report offers in-depth assessment of the growth and other aspects of the Bevacizumab Biosimilar market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Bevacizumab Biosimilar Market Share Analysis
Bevacizumab Biosimilar competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Bevacizumab Biosimilar sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Bevacizumab Biosimilar sales, revenue and market share for each player covered in this report.
The major players covered in Bevacizumab Biosimilar are:
Pfizer
Celgene Corporation
Biocon
Allergan
Beaconpharma
Amgen
Hetero Drugs
Bevacizumab
Reliance lifesciences
Fujifilm Kyowa Kirin Biologics
Among other players domestic and global, Bevacizumab Biosimilar market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Bevacizumab Biosimilar product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Bevacizumab Biosimilar, with price, sales, revenue and global market share of Bevacizumab Biosimilar in 2018 and 2019.
Chapter 3, the Bevacizumab Biosimilar competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bevacizumab Biosimilar breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Bevacizumab Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Bevacizumab Biosimilar sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Bevacizumab Biosimilar Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Bevacizumab Biosimilar Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 100mg
1.2.3 400mg
1.3 Market Analysis by Application
1.3.1 Overview: Global Bevacizumab Biosimilar Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Colorectal Cancer
1.3.3 Lung Cancer
1.3.4 Breast Cancer
1.3.5 Renal Cancer
1.3.6 Brain Cancer
1.3.7 Other
1.4 Overview of Global Bevacizumab Biosimilar Market
1.4.1 Global Bevacizumab Biosimilar Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Celgene Corporation
2.2.1 Celgene Corporation Details
2.2.2 Celgene Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Celgene Corporation SWOT Analysis
2.2.4 Celgene Corporation Product and Services
2.2.5 Celgene Corporation Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Biocon
2.3.1 Biocon Details
2.3.2 Biocon Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Biocon SWOT Analysis
2.3.4 Biocon Product and Services
2.3.5 Biocon Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Allergan
2.4.1 Allergan Details
2.4.2 Allergan Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Allergan SWOT Analysis
2.4.4 Allergan Product and Services
2.4.5 Allergan Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Beaconpharma
2.5.1 Beaconpharma Details
2.5.2 Beaconpharma Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Beaconpharma SWOT Analysis
2.5.4 Beaconpharma Product and Services
2.5.5 Beaconpharma Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Amgen
2.6.1 Amgen Details
2.6.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Amgen SWOT Analysis
2.6.4 Amgen Product and Services
2.6.5 Amgen Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Hetero Drugs
2.7.1 Hetero Drugs Details
2.7.2 Hetero Drugs Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Hetero Drugs SWOT Analysis
2.7.4 Hetero Drugs Product and Services
2.7.5 Hetero Drugs Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Bevacizumab
2.8.1 Bevacizumab Details
2.8.2 Bevacizumab Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Bevacizumab SWOT Analysis
2.8.4 Bevacizumab Product and Services
2.8.5 Bevacizumab Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Reliance lifesciences
2.9.1 Reliance lifesciences Details
2.9.2 Reliance lifesciences Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Reliance lifesciences SWOT Analysis
2.9.4 Reliance lifesciences Product and Services
2.9.5 Reliance lifesciences Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Fujifilm Kyowa Kirin Biologics
2.10.1 Fujifilm Kyowa Kirin Biologics Details
2.10.2 Fujifilm Kyowa Kirin Biologics Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Fujifilm Kyowa Kirin Biologics SWOT Analysis
2.10.4 Fujifilm Kyowa Kirin Biologics Product and Services
2.10.5 Fujifilm Kyowa Kirin Biologics Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Bevacizumab Biosimilar Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Bevacizumab Biosimilar Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Bevacizumab Biosimilar Manufacturer Market Share in 2019
3.3.2 Top 6 Bevacizumab Biosimilar Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Bevacizumab Biosimilar Sales, Revenue and Market Share by Regions
4.1.1 Global Bevacizumab Biosimilar Sales and Market Share by Regions (2015-2020)
4.1.2 Global Bevacizumab Biosimilar Revenue and Market Share by Regions (2015-2020)
4.2 North America Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
4.3 Europe Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
4.5 South America Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Bevacizumab Biosimilar Sales, Revenue and Market Share by Country
5.1.1 North America Bevacizumab Biosimilar Sales and Market Share by Country (2015-2020)
5.1.2 North America Bevacizumab Biosimilar Revenue and Market Share by Country (2015-2020)
5.2 United States Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
5.3 Canada Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
5.4 Mexico Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Bevacizumab Biosimilar Sales, Revenue and Market Share by Country
6.1.1 Europe Bevacizumab Biosimilar Sales and Market Share by Country (2015-2020)
6.1.2 Europe Bevacizumab Biosimilar Revenue and Market Share by Country (2015-2020)
6.2 Germany Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
6.3 UK Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
6.4 France Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
6.5 Russia Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
6.6 Italy Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Bevacizumab Biosimilar Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Bevacizumab Biosimilar Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Bevacizumab Biosimilar Revenue and Market Share by Regions (2015-2020)
7.2 China Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
7.3 Japan Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
7.4 Korea Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
7.5 India Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
7.7 Australia Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Bevacizumab Biosimilar Sales, Revenue and Market Share by Country
8.1.1 South America Bevacizumab Biosimilar Sales and Market Share by Country (2015-2020)
8.1.2 South America Bevacizumab Biosimilar Revenue and Market Share by Country (2015-2020)
8.2 Brazil Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
8.3 Argentina Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Bevacizumab Biosimilar Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Bevacizumab Biosimilar Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Bevacizumab Biosimilar Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
9.3 Turkey Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
9.4 Egypt Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
9.5 South Africa Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Bevacizumab Biosimilar Sales and Market Share by Type (2015-2020)
10.2 Global Bevacizumab Biosimilar Revenue and Market Share by Type (2015-2020)
10.3 Global Bevacizumab Biosimilar Price by Type (2015-2020)
11 Global Bevacizumab Biosimilar Market Segment by Application
11.1 Global Bevacizumab Biosimilar Sales Market Share by Application (2015-2020)
11.2 Global Bevacizumab Biosimilar Revenue Market Share by Application (2015-2020)
11.3 Global Bevacizumab Biosimilar Price by Application (2015-2020)
12 Market Forecast
12.1 Global Bevacizumab Biosimilar Sales, Revenue and Growth Rate (2021-2025)
12.2 Bevacizumab Biosimilar Market Forecast by Regions (2021-2025)
12.2.1 North America Bevacizumab Biosimilar Market Forecast (2021-2025)
12.2.2 Europe Bevacizumab Biosimilar Market Forecast (2021-2025)
12.2.3 Asia-Pacific Bevacizumab Biosimilar Market Forecast (2021-2025)
12.2.4 South America Bevacizumab Biosimilar Market Forecast (2021-2025)
12.2.5 Middle East & Africa Bevacizumab Biosimilar Market Forecast (2021-2025)
12.3 Bevacizumab Biosimilar Market Forecast by Type (2021-2025)
12.3.1 Global Bevacizumab Biosimilar Sales Forecast by Type (2021-2025)
12.3.2 Global Bevacizumab Biosimilar Market Share Forecast by Type (2021-2025)
12.4 Bevacizumab Biosimilar Market Forecast by Application (2021-2025)
12.4.1 Global Bevacizumab Biosimilar Sales Forecast by Application (2021-2025)
12.4.2 Global Bevacizumab Biosimilar Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Bevacizumab Biosimilar Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Bevacizumab Biosimilar by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Bevacizumab Biosimilar Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Pfizer Basic Information, Manufacturing Base and Competitors
Table 8. Pfizer Bevacizumab Biosimilar Major Business
Table 9. Pfizer Bevacizumab Biosimilar Total Revenue (USD Million) (2017-2018)
Table 10. Pfizer SWOT Analysis
Table 11. Pfizer Bevacizumab Biosimilar Product and Services
Table 12. Pfizer Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Celgene Corporation Basic Information, Manufacturing Base and Competitors
Table 14. Celgene Corporation Bevacizumab Biosimilar Major Business
Table 15. Celgene Corporation Bevacizumab Biosimilar Total Revenue (USD Million) (2017-2018)
Table 16. Celgene Corporation SWOT Analysis
Table 17. Celgene Corporation Bevacizumab Biosimilar Product and Services
Table 18. Celgene Corporation Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Biocon Basic Information, Manufacturing Base and Competitors
Table 20. Biocon Bevacizumab Biosimilar Major Business
Table 21. Biocon Bevacizumab Biosimilar Total Revenue (USD Million) (2017-2018)
Table 22. Biocon SWOT Analysis
Table 23. Biocon Bevacizumab Biosimilar Product and Services
Table 24. Biocon Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Allergan Basic Information, Manufacturing Base and Competitors
Table 26. Allergan Bevacizumab Biosimilar Major Business
Table 27. Allergan Bevacizumab Biosimilar Total Revenue (USD Million) (2017-2018)
Table 28. Allergan SWOT Analysis
Table 29. Allergan Bevacizumab Biosimilar Product and Services
Table 30. Allergan Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Beaconpharma Basic Information, Manufacturing Base and Competitors
Table 32. Beaconpharma Bevacizumab Biosimilar Major Business
Table 33. Beaconpharma Bevacizumab Biosimilar Total Revenue (USD Million) (2017-2018)
Table 34. Beaconpharma SWOT Analysis
Table 35. Beaconpharma Bevacizumab Biosimilar Product and Services
Table 36. Beaconpharma Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Amgen Basic Information, Manufacturing Base and Competitors
Table 38. Amgen Bevacizumab Biosimilar Major Business
Table 39. Amgen Bevacizumab Biosimilar Total Revenue (USD Million) (2017-2018)
Table 40. Amgen SWOT Analysis
Table 41. Amgen Bevacizumab Biosimilar Product and Services
Table 42. Amgen Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Hetero Drugs Basic Information, Manufacturing Base and Competitors
Table 44. Hetero Drugs Bevacizumab Biosimilar Major Business
Table 45. Hetero Drugs Bevacizumab Biosimilar Total Revenue (USD Million) (2017-2018)
Table 46. Hetero Drugs SWOT Analysis
Table 47. Hetero Drugs Bevacizumab Biosimilar Product and Services
Table 48. Hetero Drugs Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Bevacizumab Basic Information, Manufacturing Base and Competitors
Table 50. Bevacizumab Bevacizumab Biosimilar Major Business
Table 51. Bevacizumab Bevacizumab Biosimilar Total Revenue (USD Million) (2017-2018)
Table 52. Bevacizumab SWOT Analysis
Table 53. Bevacizumab Bevacizumab Biosimilar Product and Services
Table 54. Bevacizumab Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Reliance lifesciences Basic Information, Manufacturing Base and Competitors
Table 56. Reliance lifesciences Bevacizumab Biosimilar Major Business
Table 57. Reliance lifesciences Bevacizumab Biosimilar Total Revenue (USD Million) (2017-2018)
Table 58. Reliance lifesciences SWOT Analysis
Table 59. Reliance lifesciences Bevacizumab Biosimilar Product and Services
Table 60. Reliance lifesciences Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Fujifilm Kyowa Kirin Biologics Basic Information, Manufacturing Base and Competitors
Table 62. Fujifilm Kyowa Kirin Biologics Bevacizumab Biosimilar Major Business
Table 63. Fujifilm Kyowa Kirin Biologics Bevacizumab Biosimilar Total Revenue (USD Million) (2017-2018)
Table 64. Fujifilm Kyowa Kirin Biologics SWOT Analysis
Table 65. Fujifilm Kyowa Kirin Biologics Bevacizumab Biosimilar Product and Services
Table 66. Fujifilm Kyowa Kirin Biologics Bevacizumab Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Global Bevacizumab Biosimilar Sales by Manufacturer (2018-2019) (K Pcs)
Table 68. Global Bevacizumab Biosimilar Revenue by Manufacturer (2018-2019) (USD Million)
Table 69. Global Bevacizumab Biosimilar Sales by Regions (2015-2020) (K Pcs)
Table 70. Global Bevacizumab Biosimilar Sales Market Share by Regions (2015-2020)
Table 71. Global Bevacizumab Biosimilar Revenue by Regions (2015-2020) (USD Million)
Table 72. North America Bevacizumab Biosimilar Sales by Countries (2015-2020) (K Pcs)
Table 73. North America Bevacizumab Biosimilar Sales Market Share by Countries (2015-2020)
Table 74. North America Bevacizumab Biosimilar Revenue by Countries (2015-2020) (USD Million)
Table 75. North America Bevacizumab Biosimilar Revenue Market Share by Countries (2015-2020)
Table 76. Europe Bevacizumab Biosimilar Sales by Countries (2015-2020) (K Pcs)
Table 77. Europe Bevacizumab Biosimilar Sales Market Share by Countries (2015-2020)
Table 78. Europe Bevacizumab Biosimilar Revenue by Countries (2015-2020) (USD Million)
Table 79. Asia-Pacific Bevacizumab Biosimilar Sales by Regions (2015-2020) (K Pcs)
Table 80. Asia-Pacific Bevacizumab Biosimilar Sales Market Share by Regions (2015-2020)
Table 81. Asia-Pacific Bevacizumab Biosimilar Revenue by Regions (2015-2020) (USD Million)
Table 82. South America Bevacizumab Biosimilar Sales by Countries (2015-2020) (K Pcs)
Table 83. South America Bevacizumab Biosimilar Sales Market Share by Countries (2015-2020)
Table 84. South America Bevacizumab Biosimilar Revenue by Countries (2015-2020) (USD Million)
Table 85. South America Bevacizumab Biosimilar Revenue Market Share by Countries (2015-2020)
Table 86. Middle East & Africa Bevacizumab Biosimilar Sales by Countries (2015-2020) (K Pcs)
Table 87. Middle East & Africa Bevacizumab Biosimilar Sales Market Share by Countries (2015-2020)
Table 88. Middle East & Africa Bevacizumab Biosimilar Revenue by Countries (2015-2020) (USD Million)
Table 89. Middle East & Africa Bevacizumab Biosimilar Revenue Market Share by Countries (2015-2020)
Table 90. Global Bevacizumab Biosimilar Sales by Type (2015-2020) (K Pcs)
Table 91. Global Bevacizumab Biosimilar Sales Share by Type (2015-2020)
Table 92. Global Bevacizumab Biosimilar Revenue by Type (2015-2020) (USD Million)
Table 93. Global Bevacizumab Biosimilar Revenue Share by Type (2015-2020)
Table 94. Global Bevacizumab Biosimilar Sales by Application (2015-2020) (K Pcs)
Table 95. Global Bevacizumab Biosimilar Sales Share by Application (2015-2020)
Table 96. Global Bevacizumab Biosimilar Sales Forecast by Regions (2021-2025) (K Pcs)
Table 97. Global Bevacizumab Biosimilar Market Share Forecast by Regions (2021-2025)
Table 98. Global Bevacizumab Biosimilar Sales Forecast by Type (2021-2025) (K Pcs)
Table 99. Global Bevacizumab Biosimilar Market Share Forecast by Type (2021-2025)
Table 100. Global Bevacizumab Biosimilar Sales Forecast by Application (2021-2025)
Table 101. Global Bevacizumab Biosimilar Market Share Forecast by Application (2021-2025)
Table 102. Direct Channel Pros & Cons
Table 103. Indirect Channel Pros & Cons
Table 104. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Bevacizumab Biosimilar Picture
Figure 2. Global Sales Market Share of Bevacizumab Biosimilar by Type in 2019
Figure 3. 100mg Picture
Figure 4. 400mg Picture
Figure 5. Bevacizumab Biosimilar Sales Market Share by Application in 2018
Figure 6. Colorectal Cancer Picture
Figure 7. Lung Cancer Picture
Figure 8. Breast Cancer Picture
Figure 9. Renal Cancer Picture
Figure 10. Brain Cancer Picture
Figure 11. Other Picture
Figure 12. Global Bevacizumab Biosimilar Market Status and Outlook (2015-2025) (USD Million)
Figure 13. United States Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Canada Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Mexico Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Germany Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 17. France Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 18. UK Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Russia Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Italy Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 21. China Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Japan Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Korea Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 24. India Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Southeast Asia Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Australia Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 27. Brazil Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Egypt Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Saudi Arabia Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 30. South Africa Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Turkey Bevacizumab Biosimilar Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Global Bevacizumab Biosimilar Sales Market Share by Manufacturer in 2019
Figure 33. Global Bevacizumab Biosimilar Revenue Market Share by Manufacturer in 2019
Figure 34. Top 3 Bevacizumab Biosimilar Manufacturer (Revenue) Market Share in 2019
Figure 35. Top 6 Bevacizumab Biosimilar Manufacturer (Revenue) Market Share in 2019
Figure 36. Key Manufacturer Market Share Trend
Figure 37. Global Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 38. Global Bevacizumab Biosimilar Revenue and Growth Rate (2015-2020) (USD Million)
Figure 39. Global Bevacizumab Biosimilar Revenue Market Share by Regions (2015-2020)
Figure 40. Global Bevacizumab Biosimilar Revenue Market Share by Regions in 2018
Figure 41. North America Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
Figure 42. Europe Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
Figure 44. South America Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
Figure 45. Middle East & Africa Bevacizumab Biosimilar Sales and Growth Rate (2015-2020)
Figure 46. North America Bevacizumab Biosimilar Revenue and Growth Rate (2015-2020) (USD Million)
Figure 47. North America Bevacizumab Biosimilar Sales Market Share by Countries (2015-2020)
Figure 48. North America Bevacizumab Biosimilar Sales Market Share by Countries in 2018
Figure 49. North America Bevacizumab Biosimilar Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 50. North America Bevacizumab Biosimilar Revenue Market Share by Countries in 2018
Figure 51. United States Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 52. Canada Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 53. Mexico Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 54. Europe Bevacizumab Biosimilar Revenue and Growth Rate (2015-2020) (USD Million)
Figure 55. Europe Bevacizumab Biosimilar Revenue Market Share by Countries (2015-2020)
Figure 56. Europe Bevacizumab Biosimilar Revenue Market Share by Countries in 2019
Figure 57. Germany Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 58. UK Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. France Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. Russia Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. Italy Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 62. Asia-Pacific Bevacizumab Biosimilar Revenue and Growth Rate (2015-2020) (USD Million)
Figure 63. Asia-Pacific Bevacizumab Biosimilar Sales Market Share by Regions 2019
Figure 64. Asia-Pacific Bevacizumab Biosimilar Revenue Market Share by Regions 2019
Figure 65. China Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. Korea Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. India Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. Southeast Asia Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 70. South America Bevacizumab Biosimilar Revenue and Growth Rate (2015-2020) (USD Million)
Figure 71. South America Bevacizumab Biosimilar Sales Market Share by Countries in 2019
Figure 72. South America Bevacizumab Biosimilar Revenue Market Share by Countries in 2019
Figure 73. Brazil Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 74. Argentina Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 75. Middle East and Africa Bevacizumab Biosimilar Revenue and Growth Rate (2015-2020) (USD Million)
Figure 76. Middle East and Africa Bevacizumab Biosimilar Sales Market Share by Countries in 2019
Figure 77. Middle East and Africa Bevacizumab Biosimilar Revenue Market Share by Countries (2015-2020)
Figure 78. Middle East and Africa Bevacizumab Biosimilar Revenue Market Share by Countries in 2019
Figure 79. Saudi Arabia Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 80. Egypt Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 81. Turkey Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 82. South Africa Bevacizumab Biosimilar Sales and Growth Rate (2015-2020) (K Pcs)
Figure 83. Global Bevacizumab Biosimilar Sales and Growth Rate (2021-2025) (K Pcs)
Figure 84. Global Bevacizumab Biosimilar Revenue and Growth Rate (2021-2025) (USD Million)
Figure 85. North America Sales Bevacizumab Biosimilar Market Forecast (2021-2025) (K Pcs)
Figure 86. Europe Sales Bevacizumab Biosimilar Market Forecast (2021-2025) (K Pcs)
Figure 87. Asia-Pacific Sales Bevacizumab Biosimilar Market Forecast (2021-2025) (K Pcs)
Figure 88. South America Sales Bevacizumab Biosimilar Market Forecast (2021-2025) (K Pcs)
Figure 89. Middle East & Africa Sales Bevacizumab Biosimilar Market Forecast (2021-2025) (K Pcs)
Figure 90. Sales Channel: Direct Channel vs Indirect Channel
バイオシミラーモノクローナル抗体の世界市場（～2026年） Biosimilar monoclonal antibodies (mAbs) are complex, large proteins of the biosimilar family used by the immune system to identify and neutralize foreign bodies, such as bacteria, viruses, and others. These antibodies are normally administered in the treatment of diseases such as rheumatoid arthriti…- 大腸がんの世界市場（～2026年） Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). The major symptoms associated with colorectal cancer include diarrhea, constipation, blood in feces, pain in abdomen, loss of appetite, loss of …
- 肺癌の世界市場（～2026年） Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. This growth can spread beyond the lung by the process of metastasis into nearby tissue or other parts of the body. Most cancers that start in the lung, known as prim…
- バイオシミラー試験・開発サービスの世界市場（～2026年） The global biosimilar testing and development services is segmented on the basis of clinical assays, comparability testing, and region. On the basis of clinical assays, it is divided into PK assay, tiered immunogenicity testing, and NAb assays. On the basis of comparability testing, it is classified…
- 肺がん治療薬の世界市場（～2026年） Market Analysis and Insights: Global Lung Cancer Therapeutics Market The global Lung Cancer Therapeutics market size is projected to reach US$ 15800 million by 2026, from US$ 14180 million in 2020, at a CAGR of 10.6%% during 2021-2026. Global Lung Cancer Therapeutics Scope and Market Size Lung Cance…